Compremium Receives FDA Breakthrough Device Designation for Non-Invasive Central Venous Pressure Measurement System and has also joined FDA’s TAP Program
Compremium AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its novel solution designed to directly measure central venous pressure (CVP) non-invasively. The device has also joined the FDA’s Total Product Life Cycle Advisory Program (TAP).
